Full year 2023 total revenue is expected to be in the range of $80.9 million to $81.1 million, an increase of 14% compared to the prior year at the estimated midpoint. Surgical Glaucoma revenues are expected to be in the range of $74.3 million to $74.4 million, an increase of 13% compared to the prior year at the estimated midpoint. Dry Eye revenues are expected to be in the range of $6.6 million to $6.7 million, an increase of 17% compared to the prior year at the estimated midpoint. The Company’s cash and cash equivalents as of December 31, 2023, was approximately $138 million, compared to $144.5 million as of September 30, 2023. Cash used in the quarter totaled approximately $6.5 million, reflecting continued operational discipline and a sequential improvement from $10.0 million cash used in the third quarter of 2023 and a decrease versus the comparative period in the prior year where cash used in the fourth quarter of 2022 was $14.8 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
- Piper says Sight Sciences reimbursement update positive, still sees ‘work to do’
- MIGS LCD withdrawals ‘takes some upside off table’ for Glaukos, says Truist
- Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
- Sight Sciences announces withdrawal of final LCDs on MIGS from five contractors